SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong5/22/2017 8:47:11 AM
   of 7424
 
Unexpected cardiovascular risk with Amgen and UCB's romosozumab and longer timeline for potential U.S. approval bodes well for Radius Health's Tymlos; shares ahead 18% premarket
  • Radius Health (NASDAQ: RDUS) is up 18% premarket on light volume after Amgen's announcement of late-stage results for osteoporosis candidate EVENITY (romosozumab) that included an unexpected cardiovascular safety signal.
  • The FDA recently approved (April) Radius' TYMLOS (abaloparatide) for the same population of high risk postmenopausal women. It carries no increased cardiovascular risk but its package insert has a boxed warning about an increased risk of osteosarcoma.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News